Is the Lao version of Revumenib-Revuforj already on the market?

Revumenib - Revuforj is a targeted drug for the treatment of relapsed or refractory acute leukemia (including AML, ALL) carrying KMT2A translocation. KMT2A translocation can occur in both children and adults with acute leukemia. Patients usually have poor prognosis and require innovative drug intervention. The US version of the original drug will be approved for marketing in November 2024, becoming the first batch of targeted drugs for this type of patients, providing new clinical treatment options.

In Laos and other Southeast Asian countries, there is currently no record of the launch of the original drug Revuforj, and there are no locally produced generic drugs of Revuforj.Revuforj. This means that patients cannot obtain drugs through regular pharmacies or medical channels and must rely on overseas transfers or clinical trials. The price of overseas original drugs is very high, usually more than 200,000 yuan per box, and the price may fluctuate due to exchange rates and logistics factors. For patients in Laos and surrounding areas, this represents both a therapeutic hope and a practical challenge.

Revemenib has clear indications and can only be used by patients with relapsed or refractory acute leukemia who carryKMT2A translocation, covering adults and children over 1 year old. It targets specific gene rearrangement abnormalities, inhibits the abnormal proliferation of leukemia cells, and intervenes in the disease process at the molecular level. This targeting makes the drug uniquely valuable in the treatment of refractory leukemia, and also requires genetic testing before drug use to ensure that the patient indeed carries the KMT2A translocation.

Although it has not yet been launched in Laos and Southeast Asia, it is expected to be gradually approved in more countries in the future as global drug approvals and clinical data accumulate. For patients and doctors, understanding the pharmacological effects, indications and access to revimenib is an important prerequisite for planning treatment plans.

Reference materials:https://www.drugs.com/monograph/revumenib.html